Endometrial hyperplasia is treated with progestin therapy or surgery, depending on whether the overgrowth contains abnormal cells (atypia). The distinction between hyperplasia with and without atypia is the single most important factor in determining your treatment path, because atypical hyperplasia carries a meaningful risk of progressing to uterine cancer.
Why the Lining Overgrows
Endometrial hyperplasia develops when your uterine lining is exposed to estrogen without enough progesterone to balance it out. Normally, progesterone signals the lining to shed each month during your period. Without that signal, the lining keeps building up and thickening instead of cycling normally.
Several conditions create this hormonal imbalance. Polycystic ovary syndrome (PCOS) is one of the most common, since irregular ovulation means progesterone isn’t produced consistently. Taking estrogen-only hormone therapy without a progestin component is another well-known cause. Obesity plays a major role too: fat tissue converts other hormones into estrogen, creating a chronic excess that stimulates the uterine lining. The heavier you are, the more estrogen your body produces through this pathway, which is why weight management is a core part of treatment.
Hyperplasia Without Atypia
When a biopsy shows thickened lining but no abnormal-looking cells, the condition is classified as hyperplasia without atypia. This is the less concerning form, and the first-line treatment is progestin, a synthetic version of progesterone that counteracts estrogen’s growth signal and encourages the lining to thin back to normal.
The most effective delivery method is a progestin-releasing intrauterine device (IUD), commonly known by the brand name Mirena. In a large comparative study published in Human Reproduction, the IUD achieved complete regression in 94.8% of patients, compared with 84% for oral progestin pills. The IUD also led to fewer hysterectomies during follow-up: 22% of IUD users eventually needed surgery versus 37% of those on oral progestins. The IUD works well partly because it delivers progestin directly to the uterine lining at a steady dose, rather than relying on you to take a daily pill.
Oral progestins, typically medroxyprogesterone acetate or megestrol acetate, are the alternative when an IUD isn’t suitable. Continuous daily dosing appears to work better than cycling the medication on and off. One randomized trial found continuous oral progestins were nearly as effective as the IUD.
Treatment typically lasts at least six months, and follow-up biopsies confirm whether the lining has returned to normal. If there’s no improvement after 12 months of treatment, or if the hyperplasia comes back after treatment ends, surgery becomes the next consideration.
Hyperplasia With Atypia
When the biopsy reveals atypical cells, the stakes are higher. Atypical hyperplasia has a real risk of either already harboring an undetected cancer or progressing to one. For this reason, the standard recommendation is a total hysterectomy with removal of both ovaries and fallopian tubes. Both ACOG and the Royal College of Obstetricians and Gynaecologists consider this the definitive treatment.
The exception is for women who want to become pregnant. In that case, progestin therapy with the IUD or oral medication can be tried as a fertility-sparing approach, with close monitoring through repeat biopsies. But this is understood as a temporary bridge to pregnancy, not a long-term solution. If progestin treatment fails to clear the atypical cells within 12 months, or if there’s any sign of progression to cancer, hysterectomy is strongly recommended. Even after successful regression and pregnancy, hysterectomy is typically offered once childbearing is complete, because relapse rates for atypical hyperplasia are high.
How Weight Loss Improves Treatment Response
Because excess body fat drives estrogen production, losing weight can meaningfully improve how well progestin therapy works. A study from the American Association for Cancer Research looked at women with obesity who had atypical hyperplasia or early endometrial cancer treated with a progestin IUD. Women who lost more than 10% of their total body weight were nearly four times more likely to respond to treatment than those who didn’t (adjusted odds ratio of 3.95).
In that study, women who had bariatric surgery lost an average of 33 kg and 86% of them hit the 10% weight loss threshold within a year. Women who tried a low-calorie diet alone lost an average of about 5 kg, and only 23% reached that same threshold. The researchers concluded that weight loss reduces the hormonal, metabolic, and inflammatory factors that drive abnormal endometrial growth, essentially working alongside the progestin rather than replacing it.
You don’t necessarily need bariatric surgery. The key finding is that the degree of weight loss matters more than how you achieve it. But for women with a BMI above 35, surgery may be the most realistic path to the kind of weight loss that makes a clinical difference.
Relapse After Successful Treatment
Even when progestin therapy works and the lining returns to normal, the condition can come back. Relapse rates differ based on the type of hyperplasia and the treatment used. In a long-term follow-up study, hyperplasia recurred in about 13.7% of women treated with the progestin IUD, compared with 30.3% of those treated with oral progestins. The IUD’s advantage held across both types, but atypical hyperplasia was more likely to return regardless of treatment method. Among IUD users, the relapse rate was about 13% for non-atypical and 27% for atypical cases. For oral progestin users, those numbers were 28% and 50%.
Relapse of atypical hyperplasia is particularly concerning. When women who relapsed went on to have hysterectomies, cancer was often found in the surgical specimen. This is why ongoing monitoring with periodic biopsies is essential after treatment, and why hysterectomy is recommended if the condition returns.
Pregnancy After Treatment
For women who chose fertility-sparing progestin therapy, the goal is to attempt pregnancy as soon as complete regression is confirmed on biopsy. Reproductive specialists generally recommend assisted reproduction, such as IVF, for the best chance of conceiving quickly. If natural conception or ovulation induction hasn’t worked within six months, IVF is typically the next step. Speed matters here because the longer the uterus goes without pregnancy or progestin protection after treatment, the higher the chance of relapse.
When Surgery Becomes the Right Choice
Hysterectomy is not just for atypical cases. For hyperplasia without atypia, surgery is appropriate in several situations:
- No regression after 12 months of progestin treatment
- Progression to atypia during follow-up monitoring
- Relapse after completing a full course of treatment
- Persistent bleeding that doesn’t improve with medical therapy
- Inability or unwillingness to continue with ongoing biopsies and hormonal treatment
For some women, the prospect of years of hormonal medication and repeat biopsies is itself a burden, and choosing surgery upfront is a reasonable decision. The procedure is a total hysterectomy, and recovery typically takes several weeks, with most women returning to normal activities within four to six weeks depending on whether it’s done laparoscopically or through an open incision.